Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 4/20 | 0.31 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374144 | 1.00 | POLB (0.33) | POLBL3MBTL1NPC1RAB9AADORA1 | |
| SCHEMBL25021979 | 0.86 | GBA1 (0.44) | L3MBTL1CYP19A1 | |
| SCHEMBL14275822 | 0.85 | TLR4 (0.31) | NPC1RAB9A | |
| SCHEMBL4760430 | 0.81 | BRD4 (0.33) | NPC1RAB9AKMT2A | |
| SCHEMBL20721708 | 0.81 | L3MBTL1 (0.36) | POLBL3MBTL1KMT2ACYP19A1 | |
| SCHEMBL14275606 | 0.81 | L3MBTL1 (0.36) | POLBL3MBTL1KMT2ACYP19A1 | |
| SCHEMBL4760434 | 0.81 | KMT2A (0.38) | NPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL4339603 | 0.80 | BRD4 (0.33) | NPC1RAB9AKMT2A | |
| SCHEMBL15088402 | 0.78 | RAB9A (0.33) | POLBL3MBTL1NPC1RAB9ASRD5A1 | |
| SCHEMBL21322343 | 0.76 | PIK3CD (0.50) | POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332509-B2 | Heterocyclic amides, a process for their preparation, compositions comprising them and their use | MERIAL LIMITED (US) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | POLB 1624/4885L3MBTL1 3678/4885NPC1 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.